In summary, temozolomide treatment for 5 days depleted MGMT in peripheral mononuclear cells in at least 76% of patients and low MGMT activity was correlated with severe thrombocytopenia during the first treatment cycle. This evidence concerns the gene MGMT and Thrombocytopenia.